Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer
Sponsor: Cancer Trials Ireland
Summary
This study examines the impact of an additional tumour test called the 21 gene Recurrence Score (OncotypeDx®), a commercially available test on a Medical Oncologist's decision to recommend chemotherapy.
Official title: The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy Prescribing in Estrogen Receptor Positive, Lymph Node Positive Early Stage Breast Cancer in Ireland
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
87
Start Date
2017-03-16
Completion Date
2021-02-02
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Locations (10)
Letterkenny University Hospital
Letterkenny, Co. Donegal, Ireland
St Vincent's University Hospital
Dublin, Dublin 4, Ireland
Mater Misericordiae University Hospital & Mater Private Hospital
Dublin, Dublin 7, Ireland
Beaumont Hospital
Dublin, Dublin 9, Ireland
Bon Secour Cork
Cork, Ireland
Cork University Hospital
Cork, Ireland
St James' Hospital
Dublin, Ireland
University Hospital Galway
Galway, Ireland
University Hospital Limerick
Limerick, Ireland
University Hospital Waterford
Waterford, Ireland